Fig. 1
4-EG ameliorates disease severity in chronic EAE and alleviates disease progression in relapsing-remitting EAE. a C57BL/6 mice were immunized with MOG35–55 and then i.p. injected with vehicle or 4-EG 100 mg/kg (n=20/group) daily starting from day 3 post-immunization. The clinical score of EAE animals was followed for 30 days. b SJL/J mice were immunized with PLP139–151 to induce EAE. Following the first remission and reaching disease score less than 1.5, SJL/J EAE mice were i.p. injected with vehicle or 4-EG 100 mg/kg (n=10/group) daily. The clinical score of EAE mice was monitored for 20 days. Statistical significance of EAE clinical score was determined as *p<0.05, **p<0.01, and ***p<0.001 by two-way ANOVA test. EAE incidence, mortality, onset of disease, maximum score, and cumulative score of C57BL/6 and SJL/J EAE were also assessed. Statistical significance was determined as **p<0.01 and ***p<0.001 by Mann-Whitney U test